Treatment of oligo-metastatic pancreatic ductal adenocarcinoma to the liver: is there a role for surgery? A narrative...

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, frequently diagnosed at an advanced stage with distant metastases.
• Metastatic PDAC has traditionally been deemed unresectable, limiting treatment options.
• Oligometastatic disease, defined as limited metastatic burden, is an emerging concept in cancer management.

Purpose of the Study:

• To investigate the efficacy of surgical resection for PDAC limited to liver metastases (oligometastases).
• To evaluate the role of perioperative chemotherapy in patients undergoing resection for liver-only PDAC metastases.
• To highlight the need for standardized definitions and further research in this area.

Main Methods:

• Review of existing research on surgical outcomes for PDAC with liver-only oligometastases.
• Analysis of patient selection criteria, focusing on those with metachronous metastases.
• Consideration of the impact of perioperative chemotherapy regimens.

Main Results:

• Promising results observed in extremely selected patients with liver-only oligometastases from PDAC.
• Positive outcomes are more evident in cases with metachronous metastases following perioperative chemotherapy.
• Surgical resection can be a viable option for carefully chosen patients.

Conclusions:

• Surgical resection may offer a benefit for select PDAC patients with liver-only oligometastases.
• Standardization of the definition of 'oligometastatic disease' in PDAC is crucial.
• Further investigation into perioperative chemotherapy and tumor biology is warranted to optimize treatment strategies.